[Applause] When I was 7 years old, I was eating a bowl of ramen and I didn't expect what came next. Suddenly, my throat started to tighten and was getting harder to breathe. But luckily, my friend's mom had a Porsche, so I was able to get to the hospital quickly.And that's where a life-saving dose of an EpiPen was administered. Today, the EpiPen is an essential medical device carried by everyone that has severe allergic reactions. And yet, the cost for it is increasing year overyear.What's causing this. Whe ...

[Music] It is time for the light round by social play. And then the lighting round is over. Are you ready.Time. Let's go to Stephen New York. Steve.Hey Big Jimmy. Chill. Thank you for all you do for us. Thank you for all you do for us every day people. Every day.Thank you. I'm in a wheelchair. This is all I can do for income.I'm on margin. I know that's not good. I own 500 shares and want to add to this.To me, it seems like a patriotic purchase as well as financial. What do you think of MP. Okay.First, I wa ...

Financial Data and Key Metrics Changes - The company announced a successful financing round of $160 million to support the launch of ANNAFILM, indicating a strong financial position for upcoming operations [52][68]. - The recent funding includes an $85 million equity raise and a $75 million revenue interest financing, providing sufficient runway through 2026 and into 2027 [68][69]. Business Line Data and Key Metrics Changes - ANNAFILM, the lead product, is a prodrug of epinephrine designed to improve the delivery and usability for patients at risk of severe allergic reactions [8][12]. - The company is also developing AQST-108 for alopecia areata, showcasing a commitment to expanding its product pipeline beyond ANNAFILM [9][65]. Market Data and Key Metrics Changes - The potential market for ANNAFILM includes over 30 million individuals at risk of severe allergic reactions, with only 5 million prescriptions written annually, indicating a significant opportunity for market penetration [12]. - The company plans to target college-age individuals, teenagers, and parents concerned about their children's safety as early adopters of ANNAFILM [52][53]. Company Strategy and Development Direction - The company aims to leverage its unique oral administration of epinephrine to differentiate itself from existing injectable products, focusing on convenience and accessibility [23][50]. - Plans for international expansion include outreach to key markets such as Europe, Canada, and Japan, with ongoing discussions with regulatory bodies like EMA and Health Canada [60][62]. Management's Comments on Operating Environment and Future Outlook - Management expressed optimism regarding the FDA's decision not to require an advisory committee meeting, viewing it as a positive sign for the approval process [42][46]. - The company is preparing for a robust commercial launch and anticipates a strong market response to ANNAFILM, particularly among demographics that prefer non-injectable options [51][52]. Other Important Information - The company has conducted extensive studies to ensure the safety and efficacy of ANNAFILM, including unique studies to assess its performance in various scenarios [23][40]. - The management emphasized the importance of transparency in their interactions with the FDA, which has been consistent and constructive throughout the review process [22][46]. Q&A Session Summary Question: What items would you say that you had in common with the Nefi product, and what are the key differences? - The company acknowledged similarities in the goal of helping patients but emphasized the unique aspects of their product and the thoroughness of their FDA submission process [16][18]. Question: How do you think about the time it takes to actually take the product compared to an EpiPen? - Management believes that the oral product will be used more quickly than an EpiPen due to behavioral factors and the convenience of not using a needle [36]. Question: What is the plan for ex-US markets? - The company is prioritizing outreach in Europe, Canada, and Japan, with plans to submit filings in these regions as they progress [60][62]. Question: Why should an investor own Aquestive now versus waiting for approval? - Management highlighted the momentum and readiness of the company for commercial launch, suggesting that now is an opportune time for investment [66]. Question: What is your DTC strategy and social media strategy? - The company plans to utilize social media for cost-effective marketing while reserving traditional DTC advertising for later stages of the product lifecycle [72][74].